α-Synuclein oligomers and clinical implications for Parkinson disease.
Identifieur interne : 000956 ( PubMed/Corpus ); précédent : 000955; suivant : 000957α-Synuclein oligomers and clinical implications for Parkinson disease.
Auteurs : Lorraine V. Kalia ; Suneil K. Kalia ; Pamela J. Mclean ; Andres M. Lozano ; Anthony E. LangSource :
- Annals of neurology [ 1531-8249 ] ; 2013.
English descriptors
- KwdEn :
- Animals, Humans, Inclusion Bodies (metabolism), Inclusion Bodies (pathology), Nerve Degeneration (metabolism), Nerve Degeneration (pathology), Oligonucleotides (metabolism), Oligonucleotides (toxicity), Parkinson Disease (metabolism), Parkinson Disease (pathology), alpha-Synuclein (metabolism), alpha-Synuclein (toxicity).
- MESH :
- chemical , metabolism : Oligonucleotides, alpha-Synuclein.
- metabolism : Inclusion Bodies, Nerve Degeneration, Parkinson Disease.
- pathology : Inclusion Bodies, Nerve Degeneration, Parkinson Disease.
- chemical , toxicity : Oligonucleotides, alpha-Synuclein.
- Animals, Humans.
Abstract
Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications.
DOI: 10.1002/ana.23746
PubMed: 23225525
Links to Exploration step
pubmed:23225525Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">α-Synuclein oligomers and clinical implications for Parkinson disease.</title><author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V" last="Kalia">Lorraine V. Kalia</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Kalia, Suneil K" sort="Kalia, Suneil K" uniqKey="Kalia S" first="Suneil K" last="Kalia">Suneil K. Kalia</name></author><author><name sortKey="Mclean, Pamela J" sort="Mclean, Pamela J" uniqKey="Mclean P" first="Pamela J" last="Mclean">Pamela J. Mclean</name></author><author><name sortKey="Lozano, Andres M" sort="Lozano, Andres M" uniqKey="Lozano A" first="Andres M" last="Lozano">Andres M. Lozano</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23225525</idno><idno type="pmid">23225525</idno><idno type="doi">10.1002/ana.23746</idno><idno type="wicri:Area/PubMed/Corpus">000956</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000956</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">α-Synuclein oligomers and clinical implications for Parkinson disease.</title><author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V" last="Kalia">Lorraine V. Kalia</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Kalia, Suneil K" sort="Kalia, Suneil K" uniqKey="Kalia S" first="Suneil K" last="Kalia">Suneil K. Kalia</name></author><author><name sortKey="Mclean, Pamela J" sort="Mclean, Pamela J" uniqKey="Mclean P" first="Pamela J" last="Mclean">Pamela J. Mclean</name></author><author><name sortKey="Lozano, Andres M" sort="Lozano, Andres M" uniqKey="Lozano A" first="Andres M" last="Lozano">Andres M. Lozano</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="eISSN">1531-8249</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Humans</term><term>Inclusion Bodies (metabolism)</term><term>Inclusion Bodies (pathology)</term><term>Nerve Degeneration (metabolism)</term><term>Nerve Degeneration (pathology)</term><term>Oligonucleotides (metabolism)</term><term>Oligonucleotides (toxicity)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>alpha-Synuclein (metabolism)</term><term>alpha-Synuclein (toxicity)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Oligonucleotides</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Inclusion Bodies</term><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Inclusion Bodies</term><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oligonucleotides</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23225525</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>25</Day></DateCreated><DateCompleted><Year>2013</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>α-Synuclein oligomers and clinical implications for Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>155-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.23746</ELocationID><Abstract><AbstractText>Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long-held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α-synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α-synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α-synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications.</AbstractText><CopyrightInformation>Copyright © 2012 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalia</LastName><ForeName>Lorraine V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Centre and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalia</LastName><ForeName>Suneil K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Andres M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS063963</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073740</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 063963</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(10):e27230</RefSource><PMID Version="1">22073131</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Genet Metab. 2003 Jun;79(2):104-9</RefSource><PMID Version="1">12809640</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Biochem Cell Biol. 2008;40(9):1835-49</RefSource><PMID Version="1">18291704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6</RefSource><PMID Version="1">8248242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2011 Oct;70(4):532-40</RefSource><PMID Version="1">22028219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 1969 Jun;17(6):557-75</RefSource><PMID Version="1">4182529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 1994 May 23;345(1):27-32</RefSource><PMID Version="1">8194594</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2012 Mar 16;287(12):9193-9</RefSource><PMID Version="1">22267729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1999 Dec;46(6):860-6</RefSource><PMID Version="1">10589538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 2002 Oct 4;322(5):1089-102</RefSource><PMID Version="1">12367530</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Nov 15;25(15):2508-15</RefSource><PMID Version="1">20818670</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2005 Jun 16;46(6):857-68</RefSource><PMID Version="1">15953415</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2012 May;26(5):1946-59</RefSource><PMID Version="1">22253473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Jan 15;24(1):32-9</RefSource><PMID Version="1">19006185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Mol Biol. 2011;670:109-23</RefSource><PMID Version="1">20967587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2011 Jul 21;475(7356):324-32</RefSource><PMID Version="1">21776078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neuropathol. 2010 Nov;120(5):641-9</RefSource><PMID Version="1">20838799</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ Case Rep. 2009;2009:null</RefSource><PMID Version="1">21686713</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9</RefSource><PMID Version="1">21325059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2010 Mar;332(3):849-57</RefSource><PMID Version="1">19934398</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Mol Genet. 2010 Jan 1;19(1):65-78</RefSource><PMID Version="1">19825844</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2012 Feb;120(3):440-52</RefSource><PMID Version="1">22060133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2007 Mar 27;46(12):3856-61</RefSource><PMID Version="1">17338548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1997 Aug 29;272(35):22364-72</RefSource><PMID Version="1">9268388</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Physiol Rev. 2011 Oct;91(4):1161-218</RefSource><PMID Version="1">22013209</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2008 May;14(5):501-3</RefSource><PMID Version="1">18391963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2010 Dec 3;285(49):38173-82</RefSource><PMID Version="1">20847048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2010 Jun 10;66(5):646-61</RefSource><PMID Version="1">20547124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 2009 Oct 21;28(20):3256-68</RefSource><PMID Version="1">19745811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Sep;50(3):293-300</RefSource><PMID Version="1">11558785</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2012 Mar;15(3):349-57</RefSource><PMID Version="1">22286176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 1998 Feb;18(2):106-8</RefSource><PMID Version="1">9462735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2009 Jul;1792(7):664-75</RefSource><PMID Version="1">19419700</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 2011 Jul 6;30(13):2520-31</RefSource><PMID Version="1">21587205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hum Genet. 1997 Mar;60(3):588-96</RefSource><PMID Version="1">9042918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 Feb;59(2):388-93</RefSource><PMID Version="1">16437559</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2005 Nov 4;123(3):383-96</RefSource><PMID Version="1">16269331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2000 Dec;3(12):1301-6</RefSource><PMID Version="1">11100151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2008 Jul 15;270(1-2):94-8</RefSource><PMID Version="1">18353371</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2010 May 19;30(20):6838-51</RefSource><PMID Version="1">20484626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2009 May;15(4):300-6</RefSource><PMID Version="1">18804399</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2009 Dec;41(12):1308-12</RefSource><PMID Version="1">19915575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 Jan 29-Feb 4;365(9457):415-6</RefSource><PMID Version="1">15680457</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2012 Mar 7;32(10):3301-5</RefSource><PMID Version="1">22399752</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2001 Jul 3;40(26):7812-9</RefSource><PMID Version="1">11425308</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008;3(4):e1867</RefSource><PMID Version="1">18382657</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(2):e14695</RefSource><PMID Version="1">21358815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8</RefSource><PMID Version="1">17210620</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2011 Jun;117(5):868-78</RefSource><PMID Version="1">21426349</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Biol. 1997 Dec;4(12):951-9</RefSource><PMID Version="1">9427660</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Neurol Disord Drug Targets. 2010 Dec;9(6):741-53</RefSource><PMID Version="1">20942788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2006 Mar;20(3):419-25</RefSource><PMID Version="1">16507759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2009 Feb;66(2):167-72</RefSource><PMID Version="1">19204152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 Feb;59(2):315-22</RefSource><PMID Version="1">16437584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Clin Exp Pathol. 2008 Jan 01;1(3):217-31</RefSource><PMID Version="1">18784814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2011 Sep;43(3):552-7</RefSource><PMID Version="1">21600984</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2003 May 8;542(1-3):147-52</RefSource><PMID Version="1">12729915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 1998 Aug;4(2):65-72</RefSource><PMID Version="1">18591091</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2009 Dec;41(12):1303-7</RefSource><PMID Version="1">19915576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2003 Jun;9(5):247-51</RefSource><PMID Version="1">12781588</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2003 Sep;4(9):727-38</RefSource><PMID Version="1">12951565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 May;26(6):993-1002</RefSource><PMID Version="1">21626544</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2007 Apr 4;27(14):3650-62</RefSource><PMID Version="1">17409229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Autophagy. 2012 Jan;8(1):98-108</RefSource><PMID Version="1">22113202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Mol Genet. 2008 Feb 1;17(3):345-56</RefSource><PMID Version="1">17947294</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2010 Nov 24;143(5):686-93</RefSource><PMID Version="1">21111230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2011 Jan;25(1):326-36</RefSource><PMID Version="1">20876215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2008 Jun 27;283(26):17962-8</RefSource><PMID Version="1">18436529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2012 Feb;35(2):92-103</RefSource><PMID Version="1">22137337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2011 Apr 20;585(8):1113-20</RefSource><PMID Version="1">21443877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1997 Jun 27;276(5321):2045-7</RefSource><PMID Version="1">9197268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2010 Jun;133(Pt 6):1772-8</RefSource><PMID Version="1">20430832</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2004 Jul;10 Suppl:S10-7</RefSource><PMID Version="1">15272267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2003 Oct 31;302(5646):841</RefSource><PMID Version="1">14593171</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1991 Nov 1;563(1-2):311-4</RefSource><PMID Version="1">1786545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 1998 Nov;4(11):1318-20</RefSource><PMID Version="1">9809558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Jan;26(1):6-17</RefSource><PMID Version="1">21322014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2008 May;14(5):504-6</RefSource><PMID Version="1">18391962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2007 Feb 2;282(5):3157-64</RefSource><PMID Version="1">17121819</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2011 Feb;121(2):715-25</RefSource><PMID Version="1">21245577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29</RefSource><PMID Version="1">17565364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(4):e19338</RefSource><PMID Version="1">21559417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Neurosci. 2012 May;47(1):139-43</RefSource><PMID Version="1">22194196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2011 Sep 1;477(7362):107-10</RefSource><PMID Version="1">21841800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2005 Aug;94(8):1668-75</RefSource><PMID Version="1">15986476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2007 Aug 22;27(34):9220-32</RefSource><PMID Version="1">17715357</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2005 Sep;58(3):411-22</RefSource><PMID Version="1">16130111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2009 Sep;35(3):385-98</RefSource><PMID Version="1">19505575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2010 Nov 30;49(47):10039-41</RefSource><PMID Version="1">21047142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2004 Feb 25;24(8):1888-96</RefSource><PMID Version="1">14985429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2012 Jun;1822(6):1070-8</RefSource><PMID Version="1">22366762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jan 15;22(2):275-8</RefSource><PMID Version="1">17149743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5</RefSource><PMID Version="1">19651612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2011 Jan;17(1):55-7</RefSource><PMID Version="1">20971030</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Neurodegener. 2011 Jun 06;6:39</RefSource><PMID Version="1">21645391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2006 Mar;54(3):197-201</RefSource><PMID Version="1">16406150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropathology. 2009 Oct;29(5):536-42</RefSource><PMID Version="1">19389076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2004 Mar 26;279(13):12924-34</RefSource><PMID Version="1">14711827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2007 Aug 31;3(8):e125</RefSource><PMID Version="1">17784787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2011 Jul 8;146(1):37-52</RefSource><PMID Version="1">21700325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72</RefSource><PMID Version="1">20720502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Feb 27;56(4):555-7</RefSource><PMID Version="1">11222808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2004 Feb;55(2):164-73</RefSource><PMID Version="1">14755719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Aug 24;63(4):678-82</RefSource><PMID Version="1">15326242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Mol Genet. 2011 Apr 1;20(7):1438-55</RefSource><PMID Version="1">21257639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropathol Appl Neurobiol. 1989 Jan-Feb;15(1):27-44</RefSource><PMID Version="1">2542825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Feb 20;37(4):583-95</RefSource><PMID Version="1">12597857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2002 May 16;34(4):521-33</RefSource><PMID Version="1">12062037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 Dec;67(12):1464-72</RefSource><PMID Version="1">20697033</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17797-802</RefSource><PMID Version="1">22006323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell. 2011 Jul 8;43(1):8-18</RefSource><PMID Version="1">21726806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2006 Jul 21;313(5785):324-8</RefSource><PMID Version="1">16794039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2004 Mar;55(3):306-19</RefSource><PMID Version="1">14991808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2012 May 4;287(19):15345-64</RefSource><PMID Version="1">22315227</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2005 Mar 4;280(9):7800-7</RefSource><PMID Version="1">15632170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 2007 May 11;368(4):1132-44</RefSource><PMID Version="1">17391701</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 Nov;67(11):1350-6</RefSource><PMID Version="1">21060011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2008 Sep;7(9):805-11</RefSource><PMID Version="1">18667360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Sep 8;437(7056):257-61</RefSource><PMID Version="1">16148934</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Oct 24;67(8):1506-8</RefSource><PMID Version="1">17060589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2010 May 7;285(19):14777-90</RefSource><PMID Version="1">20220138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1997 Aug 28;388(6645):839-40</RefSource><PMID Version="1">9278044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2010 Mar 3;30(9):3409-18</RefSource><PMID Version="1">20203200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2012 May 25;149(5):1048-59</RefSource><PMID Version="1">22632969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Struct Mol Biol. 2004 Dec;11(12):1215-22</RefSource><PMID Version="1">15543156</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 Apr;132(Pt 4):1093-101</RefSource><PMID Version="1">19155272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Oct 23;57(8):1497-9</RefSource><PMID Version="1">11673599</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Nov 16;31(46):16884-94</RefSource><PMID Version="1">22090514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9</RefSource><PMID Version="1">15451224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurochem Res. 2013 Jan;38(1):201-7</RefSource><PMID Version="1">23117422</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Oct;114 ( Pt 5):2283-301</RefSource><PMID Version="1">1933245</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Cell Biol. 2002 Feb;4(2):160-4</RefSource><PMID Version="1">11813001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2011 Jun;12(6):359-66</RefSource><PMID Version="1">21587290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Sep;15(5):884-8</RefSource><PMID Version="1">11009195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Genet Metab. 2004 Jul;82(3):192-207</RefSource><PMID Version="1">15234332</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2009 Feb 4;29(5):1480-5</RefSource><PMID Version="1">19193894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1998 Sep;51(3):890-2</RefSource><PMID Version="1">9748052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Nov 16;75(20):1766-72</RefSource><PMID Version="1">20962290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell. 2004 Jul 2;15(1):95-105</RefSource><PMID Version="1">15225551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neuropathol. 2010 Aug;120(2):155-67</RefSource><PMID Version="1">20232069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Dev. 2000 Sep;22 Suppl 1:S87-91</RefSource><PMID Version="1">10984666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2002 Apr 4;416(6880):535-9</RefSource><PMID Version="1">11932745</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Oct 22;361(17):1651-61</RefSource><PMID Version="1">19846850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2009 Apr 24;284(17):11048-58</RefSource><PMID Version="1">19141614</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 Jul;132(Pt 7):1783-94</RefSource><PMID Version="1">19286695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2010 Jul;33(7):317-25</RefSource><PMID Version="1">20493564</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2011 Jan 19;305(3):275-83</RefSource><PMID Version="1">21245183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(12):e15245</RefSource><PMID Version="1">21209946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2011 Oct 6;72(1):57-71</RefSource><PMID Version="1">21982369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</RefSource><PMID Version="1">12498954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2002 Nov;110(10):1429-39</RefSource><PMID Version="1">12438441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1983 Dec 24-31;2(8365-66):1457-9</RefSource><PMID Version="1">6140548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Jan 26;31(4):1355-65</RefSource><PMID Version="1">21273420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2004 Dec 16;44(6):931-45</RefSource><PMID Version="1">15603737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Oct 8;339(15):1044-53</RefSource><PMID Version="1">9761807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell. 2002 Apr;9(4):789-98</RefSource><PMID Version="1">11983170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2006 Nov;21(11):1806-23</RefSource><PMID Version="1">16972273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2010 Nov;9(11):1128-38</RefSource><PMID Version="1">20846907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2002 Dec 19;36(6):1007-19</RefSource><PMID Version="1">12495618</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Mol Genet. 2005 Dec 15;14(24):3801-11</RefSource><PMID Version="1">16239241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2012 Mar 7;32(10):3306-20</RefSource><PMID Version="1">22399753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2004 Aug;18(11):1315-7</RefSource><PMID Version="1">15180968</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2008 May;22(5):1327-34</RefSource><PMID Version="1">18162487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2010 Nov;11(11):777-88</RefSource><PMID Version="1">20944667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2005 Dec;128(Pt 12):2786-96</RefSource><PMID Version="1">16272164</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropathol Exp Neurol. 2004 Jul;63(7):742-9</RefSource><PMID Version="1">15290899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Oct 15;24(13):1998-2001</RefSource><PMID Version="1">19735093</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9</RefSource><PMID Version="1">12376616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73</RefSource><PMID Version="1">12084935</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS403731</OtherID><OtherID Source="NLM">PMC3608838</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23225525</ArticleId><ArticleId IdType="doi">10.1002/ana.23746</ArticleId><ArticleId IdType="pmc">PMC3608838</ArticleId><ArticleId IdType="mid">NIHMS403731</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000956 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000956 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23225525
|texte= α-Synuclein oligomers and clinical implications for Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23225525" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |